Frontiers in Neurology (Aug 2022)
Phase I/II trial of local interstitial chemotherapy with arsenic trioxide in patients with newly diagnosed glioma
- Dayong Han,
- Dayong Han,
- Dayong Han,
- Lei Teng,
- Lei Teng,
- Lei Teng,
- Xiaoxiong Wang,
- Xiaoxiong Wang,
- Xiaoxiong Wang,
- Yunbo Zhen,
- Yunbo Zhen,
- Yunbo Zhen,
- Xiaofeng Chen,
- Xiaofeng Chen,
- Xiaofeng Chen,
- Mingchun Yang,
- Mingchun Yang,
- Mingchun Yang,
- Ming Gao,
- Ming Gao,
- Ming Gao,
- Guang Yang,
- Guang Yang,
- Guang Yang,
- Mingyang Han,
- Ligang Wang,
- Ligang Wang,
- Ligang Wang,
- Jiajun Xu,
- Jiajun Xu,
- Jiajun Xu,
- Yue Li,
- Alina Shumadalova,
- Shiguang Zhao,
- Shiguang Zhao,
- Shiguang Zhao,
- Shiguang Zhao
Affiliations
- Dayong Han
- Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
- Dayong Han
- Institute of Brain Science, Harbin Medical University, Harbin, China
- Dayong Han
- Institute of Neuroscience, Sino-Russian Medical Research Center, Harbin Medical University, Harbin, China
- Lei Teng
- Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
- Lei Teng
- Institute of Brain Science, Harbin Medical University, Harbin, China
- Lei Teng
- Institute of Neuroscience, Sino-Russian Medical Research Center, Harbin Medical University, Harbin, China
- Xiaoxiong Wang
- Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
- Xiaoxiong Wang
- Institute of Brain Science, Harbin Medical University, Harbin, China
- Xiaoxiong Wang
- Institute of Neuroscience, Sino-Russian Medical Research Center, Harbin Medical University, Harbin, China
- Yunbo Zhen
- Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
- Yunbo Zhen
- Institute of Brain Science, Harbin Medical University, Harbin, China
- Yunbo Zhen
- Institute of Neuroscience, Sino-Russian Medical Research Center, Harbin Medical University, Harbin, China
- Xiaofeng Chen
- Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
- Xiaofeng Chen
- Institute of Brain Science, Harbin Medical University, Harbin, China
- Xiaofeng Chen
- Institute of Neuroscience, Sino-Russian Medical Research Center, Harbin Medical University, Harbin, China
- Mingchun Yang
- Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
- Mingchun Yang
- Institute of Brain Science, Harbin Medical University, Harbin, China
- Mingchun Yang
- Institute of Neuroscience, Sino-Russian Medical Research Center, Harbin Medical University, Harbin, China
- Ming Gao
- Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
- Ming Gao
- Institute of Brain Science, Harbin Medical University, Harbin, China
- Ming Gao
- Institute of Neuroscience, Sino-Russian Medical Research Center, Harbin Medical University, Harbin, China
- Guang Yang
- Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
- Guang Yang
- Institute of Brain Science, Harbin Medical University, Harbin, China
- Guang Yang
- Institute of Neuroscience, Sino-Russian Medical Research Center, Harbin Medical University, Harbin, China
- Mingyang Han
- Department of Neurosurgery, Shenzhen University General Hospital, Shenzhen, China
- Ligang Wang
- Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
- Ligang Wang
- Institute of Brain Science, Harbin Medical University, Harbin, China
- Ligang Wang
- Institute of Neuroscience, Sino-Russian Medical Research Center, Harbin Medical University, Harbin, China
- Jiajun Xu
- Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
- Jiajun Xu
- Institute of Brain Science, Harbin Medical University, Harbin, China
- Jiajun Xu
- Institute of Neuroscience, Sino-Russian Medical Research Center, Harbin Medical University, Harbin, China
- Yue Li
- Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
- Alina Shumadalova
- Department of General Chemistry, Bashkir State Medical University, Ufa, Russia
- Shiguang Zhao
- Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
- Shiguang Zhao
- Institute of Brain Science, Harbin Medical University, Harbin, China
- Shiguang Zhao
- Institute of Neuroscience, Sino-Russian Medical Research Center, Harbin Medical University, Harbin, China
- Shiguang Zhao
- Department of Neurosurgery, Shenzhen University General Hospital, Shenzhen, China
- DOI
- https://doi.org/10.3389/fneur.2022.1001829
- Journal volume & issue
-
Vol. 13
Abstract
BackgroundGlioma is the most common primary brain tumor in adults with poor prognosis. The glioma patients benefit from STUPP strategy, including maximum and safe resection and adjuvant radiotherapy and chemotherapy. Arsenic trioxide could inhibit various tumors. However, it is a challenge to evaluate the efficiency and safety of srsenic trioxide in glioma patients.ObjectiveThe arsenic trioxide has the potent therapeutic effect on glioma. However, the safety and efficacy of local interstitial chemotherapy with arsenic trioxide in newly diagnosed glioma patients is unclear.MethodsAll patients received partial or complete tumor resection and intraoperative implantation of Ommaya reservoirs followed by standard radiotherapy. Arsenic trioxide with the starting dose 0.3 mg was administered via an Ommaya reservoir catheter inserted into the tumor cavity for 5 consecutive days every 3 months for a total of eight cycles unless tumor progression or excessive toxicity was observed.ResultsNo hematological or grade 4 non-hematological toxicity was observed in any patient during arsenic trioxide treatment. The maximum tolerated dose of 1.5 mg of arsenic trioxide was safe and well tolerated. The median overall survival for WHO grade 3 glioma was 33.6 months, and for glioblastoma was 13.9 months. The median progression-free survival for WHO grade 2 glioma was 40.3 months, for grade 3 glioma was 21.5 months, and for glioblastoma was 9.5 months.ConclusionThese results suggest that arsenic trioxide is safe and well tolerated with local delivery into the tumor cavity of the brain, and the dose recommended for a phase II trial is 1.5 mg.
Keywords
